The global antisense and RNAi therapeutics market size is
expected to reach USD 1.81 billion by 2025, according to a new report by Grand
View Research, Inc., recording an 8.6% CAGR during the forecast period. Rising
instances of external funding to conduct clinical studies pertaining to
introduction of novel drug moieties plays a vital role in the process of new
product development. This fuels market growth.
Multinational healthcare establishments promote awareness and aid in
finding novel therapies for treatment of different disorders. Private
institutes such as California Institute of Regenerative Medicine and ALS Association
are involved in conducting trials by funding research institutes and
pharmaceutical organizations and this is expected to significantly fuel sector
growth. Moreover, government initiatives for speeding the development of drug
delivery platforms in order to reduce disease burden are attributive for
industrial growth.
Antisense and RNAi therapeutics services are applicable in treatment of
a wide range of diseases that target nucleic acid and affect cell growth cycle.
miRNA is attracting considerable interest in its ability to restore gene
expression and correct protein production, thereby influencing industrial
progress. Developments that involve the research of using different routes to
deliver the desired effect of candidate moiety before its removal from blood
are anticipated to fuel sector growth.
However, challenges associated with drug delivery are expected to impede
growth to a certain extent. Delivery technologies that enable mitigation of
off-target effects and undesirable immunological stimulation need to be
introduced in order to reduce the effect of restraining factors.
Full research report on antisense
and RNAi therapeutics market analysis: https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
Further key findings from the report suggest:
·
RNA interference technology accounted for
the largest share in market revenue in 2016 owing to advantages associated with
this technology over antisense technology
·
Based on the triggering of RNA molecules
this technology is segmented into siRNA and miRNA. Owing to significant
involvement of miRNA in maintaining a cell’s identity, these are used to
provide deep insight into cancer metastasis. siRNA is highly specific and
allows induction at advanced stages of cancer growth as compared to
chemotherapy. This has resulted in attaining the largest share in oncology
applications
·
Usage of RNAi therapy to selectively target
SNPs in genetic disorders will provide this segment a number of potential
treatment avenues over the forecast period
·
Extensive R&D programs carried out to
develop an efficient method for delivery of RNA silencing therapeutic products
is anticipated to propel growth. These R&D programs are based on obtaining
desired pharmacological action prior to removal of the product from the
cytoplasm and systemic circulation
·
Isis Pharmaceuticals/ Ionis
Pharmaceuticals, GSK, Alnylam Pharmaceuticals, Marina Biosciences,
Sanofi-Genzyme, Quark Pharmaceuticals, Gene Signal, and Benitec Biopharma are
major companies in the market involved in development and commercialization of
products
·
Strong product portfolio in different
phases of clinical trials and preclinical development programs is expected to
contribute to the growth of this industry.
View more reports of this category by Grand View Research
at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global antisense and RNAi
therapeutics market on the basis of technology, application, route of
administration, and region:
Antisense &
RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)
·
RNA Interference
o siRNA
o miRNA
·
Antisense RNA
Antisense &
RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)
·
Oncology
·
Cardiovascular
·
Respiratory Disorders
·
Renal Diseases
·
Neurodegenerative Disorders
·
Genetic Disorders
·
Infectious Diseases
·
Other
Antisense &
RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 -
2025)
·
Pulmonary Delivery
·
Intravenous Injections
·
Intradermal Injections
·
Intraperitoneal Injections
·
Topical Delivery
·
Other Delivery Methods
Antisense &
RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o U.K.
·
Asia Pacific
o Japan
o China
·
Latin America
o Brazil
·
Middle East & Africa
o South Africa
Access Full Press Release of this
Report:
https://www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market
https://www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
